. In general, the molecular mechanisms through which anti-metabolites induce cell death are poorly understood.
Another means of interfering with replication is to exploit DNA strand breaks that arise naturally during the process of DNA synthesis. Topoisomerases are a group of enzymes that resolve torsional strains imposed on the double helix during DNA replication. They induce transient DNA breaks to relax supercoiled DNA or allow DNA strands to pass through each other 8 . resealing of these breaks can be prevented by the use of topoisomerase poisons that trap the enzymes in complex with the DNA. The nature of the damage that is caused depends on which type of enzyme is targeted. Topoisomerase II poisons cause DSBs, and topoisomerase I poisons cause positive supercoils in advance of replication forks 134 and replication-associated DSBs 1,2 . This is a strategy commonly used for cancer treatment.
Ionizing radiation and radiomimetic agents such as bleomycin cause replication-independent DSBs that can kill non-replicating cells. In addition, such treatments can also rapidly prevent DNA replication by activation of cell-cycle checkpoints to avoid formation of toxic DNA replication lesions 9 . Cell-cycle checkpoints are regulated by effector kinases, such as ataxia telangiectasia mutated (ATM) and ATM and rad3-related (ATr) [10] [11] [12] , which regulate the activities of downstream checkpoint proteins, such as checkpoint kinases 1 (CHK1) and 2 (CHK2). Defects in DNA damage checkpoint pathways result in sensitivity to a range of anticancer treatments, for example, loss of ATM results in sensitivity to ionizing radiation 13 . The triggering of these checkpoints and subsequent DNA repair activity largely determines the efficacy of anticancer drugs in causing tumour regression.
Efficient repair of chemotherapy lesions Direct DSBs are mainly repaired by non-homologous end joining 14 , whereas replication-associated DSBs are repaired by homologous recombination (Hr) 15 and related replication repair pathways. DNA adducts, such as those created by alkylating agents, may be excised and repaired before they are confronted by the replication machinery. This is achieved by base-excision repair, excising a single damaged DNA base or a short strand containing the damaged base 16 or nucleotide-excision repair (Ner), which excises a single-stranded DNA molecule of approximately 24-30 base pairs containing the DNA lesion 17, 18 . Damaged DNA can also be repaired without removal of the damaged base, in a process that directly reverses the DNA alkylation 19 . The o-6-methylguanine-DNA methyltransferase (MGMT) is an alkyltransferase that removes alkylations on the o 6 position of guanine produced by anticancer drugs such as temozolomide 20 , and the DNA dioxygenases ABH2 (also known as AlKBH2) and ABH3 (also known as AlKBH3) revert 1-methyladenine and 3-methylcytosine back to adenine or cytosine respectively 21 . The repair of alkylated lesions is thought to be quick, with the majority of lesions probably being repaired within one hour. If the lesions are removed before the initiation of replication, the efficiency of alkylating agents in killing the tumour is significantly reduced. Thus, modulation of DNA repair clearly influences the efficacy of alkylating agents, and resistance to alkylating agents is often explained by increased expression and/or activity of DNA repair proteins.
whereas most DNA repair pathways mediate resistance to DNA damage, mismatch repair is actually required for the toxicity of several anticancer drugs (FIG. 1) . This has been explained by the 'futile repair cycle' model in which mismatch repair removes the newly inserted intact base instead of the damaged base, triggering subsequent rounds of futile repair which can be deleterious to the cell 22 . It is also possible that mismatch repair might have an important role in triggering checkpoint signalling and apoptosis, which might mediate increased cytotoxicity 23 . It has been established that a defect in mismatch repair is associated with resistance to many, but not all, DNA-damaging anticancer agents, such as monofunctional alkylating agents and cisplatin, as well as the antimetabolite 6-thioguanine 7, 22, 24 . It should be noted that mismatch repair acts directly at replication forks and can therefore not prevent them from encountering damage.
Collapse of replication forks during DNA synthesis can be avoided by bypassing DNA lesions in a process called translesion synthesis 25, 26 . This process is carried out by switching the regular polymerases, ε and δ, which are responsible for leading and lagging strand synthesis, respectively 27, 28 , to polymerases with different substrate specificities, thus enabling them to bypass different types of damaged bases 29 . once a replication fork stalls or collapses, other repair pathways are required to permit resumption of replication. Collapsed replication forks are recognized by the checkpoint machinery, which will in turn trigger
At a glance
• Several cancer chemotherapy drugs work by producing excessive DNA damage that causes cell death directly or following DNA replication. Survival is promoted through repair of these lesions by a number of DNA repair pathways.
• The efficacy of anticancer drugs is highly influenced by cellular DNA repair capacity. Inhibitors of DNA repair increase the efficacy of DNA-damaging anticancer drugs in preclinical models. Small-molecule inhibitors of DNA repair have been combined with conventional chemotherapy drugs in several phase I-II clinical trials.
• Tumour development can be associated with perturbed DNA damage response and repair pathways. This perturbation results in reduced DNA repair capacity and increased genetic instability in tumour cells. Defects in one DNA repair pathway can be compensated for by other pathways. Such compensating pathways can be identified in synthetic lethality screens and then specifically targeted for treatment of DNA repair-defective tumours.
• Evidence indicates that inhibitors of DNA repair pathways can work as single agents for the targeted treatment of DNA repair-defective cancers. This hypothesis is currently being tested in phase II trials in which patients with breast or ovarian cancers that are defective in homologous recombination are being treated with a poly(ADP-ribose) polymerase inhibitor.
• Tumours often exhibit replication stress as a consequence of oncogene-induced growth signals or hypoxia-induced replication arrest. We propose that DNA repair inhibitors could be used to prevent the repair of replication lesions present in tumour cells and convert them into fatal replication lesions that specifically kill cancer cells.
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DNA dioxygenases
A class of enzymes that directly reverse DNA base methylations through an oxidation mechanism. The human DNA dioxygenase ABH2 is thought to act at replication forks.
Mismatch repair
A process that acts during DNA replication to correct base-pairing errors made by the DNA polymerases. and bifunctional alkylators (c) induce DNA base modifications, which interfere with DNA synthesis. Lesions produced by some alkylators are processed into toxic lesions in a mismatch repair-dependent manner. The baseexcision repair (BER) and nucleotide-excision repair (NER) pathways are, together with alkyltransferases (ATs), major repair pathways, whereas other repair pathways repair toxic replication lesions, such as those produced by interstrand crosslinks. 
Endonuclease-mediated repair
A repair pathway that introduces a DNA singlestrand break in a DNA structure to facilitate continuous repair.
RecQ-mediated repair
A repair pathway that unwinds complex DNA structure to facilitate repair.
Therapeutic index
The therapeutic index describes the ability of a treatment strategy to kill cancer cells in preference to cells in normal tissues.
cell-cycle arrest 12 , DNA repair 30 or cell death through apoptosis or senescence [31] [32] [33] . Although we know little of the nature of replication lesions, there is an increasing body of information concerning pathways that repair them. Hr has a central role in the repair of most replication lesions formed by anticancer drugs 5, 6, 15, 34 . There are several ways by which Hr is used to restart replication. The sequence identity between two newly synthesised DNA molecules can be used to restart replication behind the replication block. Also, recombination can be used to bypass DNA lesions in a process called template switching 35 . other repair pathways active at replication forks involve the Fanconi anaemia (FA) repair pathway 36 , endonuclease-mediated repair, such as that mediated by the MUS81 endonuclease 37 , and RecQ-mediated repair, which involves DNA helicases such as Bloom syndrome (BlM) 38 , werner syndrome (wrN) 39, 40 and other members of the recQ family of helicases 41 . Several of the proteins in these pathways have been found to be directly linked with Hr 42 or the resolution of recombination products such as Holliday junctions 38, 40, 43, 44 . However, cells that are defective in these pathways show distinct differences from Hrdefective cells, indicating that they represent different but overlapping repair pathways 45 . Cells defective in a specific DNA repair pathway exhibit sensitivity to drugs producing DNA lesions that are normally repaired by that pathway. This sensitivity has been exploited to isolate hamster cell lines showing hypersensitivity to cancer treatments such as etoposide, mitomycin C and ionizing radiation, and also to allow cloning of genes involved in DNA repair 46 . The DNA repair pathways involved in the repair of damage caused by various anticancer agents are summarized in FIG. 1. These DNA repair pathways can have increased activity in tumour cells, resulting in resistance to chemotherapeutic drugs 47 . Importantly, these DNA repair pathways can be inhibited pharmacologically to potentially increase the efficacy or specificity of anticancer agents.
DNA repair inhibitors in combination therapy
The basic understanding of DNA repair, from the principles of the DNA lesions created to the pathways that are capable of repairing these lesions, has increased considerably during recent years. This knowledge permits rational combination of cytotoxic agents and inhibitors of DNA repair to enhance tumour-cell killing.
Understanding lesions and repair pathways enables the use of DNA-repair inhibitors to exploit tumour defects or cancer-specific replication lesions
. Several inhibitors of DNA repair have been developed as clinical agents and clinical trials are ongoing (TABlE 1) .
Sensitizers to alkylating agents. Despite the adverse side effects caused by alkylating agents on bone marrow and other normal tissues, drugs such as cyclophosphamide, ifosfamide, chlorambucil, melphalan and dacarbazine remain some of the most commonly prescribed chemotherapies in adults and children with various solid and haematological malignancies, particularly in combination with anthracyclines and steroids in multiagent regimens. More recently, a DNA alkylator and methylator developed in the 1980s, temozolomide (an oral prodrug that crosses the blood-brain barrier), has changed clinical practice in the treatment of high-grade gliomas in adults and children 48, 49 . A class of agents currently being tested in clinical trials in combination with temozolomide therapy consists of the pseudosubstrates for MGMT. The lead compounds in this class have been O 6 -benzylguanine 50 and lomeguatrib (AstraZeneca, london, UK); the latter is also known as O 6 -(4-bromothenyl)guanine or PaTrin-2. resistance to o 6 -alkylating agents can be overcome in preclinical models by depletion of MGMT 51 and a relationship exists between MGMT activity and resistance to chloroethylating nitrosoureas and methylating agents in tumour cells grown in vitro and in xenograft models 52 . O 6 -Benzylguanine and lomeguatrib have recently been tested in phase I-II clinical trials and biologically effective doses have been established for both agents 53 . In the case of O 6 -benzylguanine, a phase I clinical trial not only defined the maximum tolerated dose (MTD) of a single dose of temozolomide when combined with O 6 -benzylguanine, but it also determined the dose of O 6 -benzylguanine that was effective in producing complete depletion of tumour MGMT activity for 48 h 54 . However, results obtained so far indicate that, when used in combination with cytotoxic chemotherapy, myelosuppression is significantly enhanced by O 6 -benzylguanine and lomeguatrib, necessitating significant reductions in the doses of alkylating agents prescribed from those used in standard chemotherapy 55 . on account of this lack of selectivity for malignant tissue versus normal bone marrow, no improvement in the therapeutic index has so far been demonstrated in clinical trials of these agents.
The combination of temozolomide with inhibitors of poly(ADP-ribose) polymerase 1 (PArP1) is currently under investigation in several clinical trials (TABlE 1) . PArP1 is required for the efficient base-excision repair of apurinic sites, the intermediate DNA lesions induced by temozolomide, and inhibition of PArP1 retards the repair of these lesions. It was originally shown in 1980 by Durkacz and Shall that specific inhibitors of PArP can prevent the rejoining of DNA strand breaks that are caused by dimethyl sulphate, resulting in demonstrable cytotoxicity in vitro 56 . However, in the absence of PArP1 inhibition, apurinic sites are not generally regarded Box 1 | Strategies using DNA repair inhibitors in cancer treatment
• DNA repair inhibitors can be used in combination with a DNA-damaging anticancer agent. This will increase the efficiency of the cancer treatment by inhibiting DNA repair-mediated removal of toxic DNA lesions.
• DNA repair inhibitors can be used as monotherapy to selectively kill cancer cells with a defect in the DNA damage response or DNA repair. Synthetic lethal interactions between a tumour defect and DNA repair pathway can be used to identify novel treatment strategies.
• In the future, DNA repair inhibitors could potentially be used to amplify tumourspecific replication lesions to selectively kill cancer cells. This strategy would take advantage of cancer-specific replication stress caused by oncogenes or the tumour microenvironment.
as major contributors to the cytotoxicity induced by temozolomide. The success of the treatment rationale adopted by current clinical trials of GPI-21016 (Guilford Pharmaceuticals, Baltimore, Maryland, USA), INo-1001 (Inotek Pharmaceuticals, Beverly, Massachusetts, USA) and AG-014699 (Pfizer GrD, la Jolla, California, USA) depends on the overall biological role of and necessity for PArP in cancer cells that are trying to repair the DNA damage induced by temozolomide. The role of PArP in DNA repair has not been fully elucidated and additional roles for PArP in DNA damage signalling or repair might explain the increased toxicity of combination treatments 57, 58 .
Platinum chemotherapies. Cisplatin, carboplatin and oxaliplatin have become three of the most commonly prescribed chemotherapeutic drugs used to treat solid cancers in patients 59 . Platinum resistance, either intrinsic or acquired during cyclical treatment, is a major clinical problem as additional agents that can be added to therapy in order to circumvent tumour resistance do not currently exist.
Platinum chemotherapy is now being tested with PArP inhibition in two clinical trials (TABlE 1) . The rationale for combining PArP inhibition with platinum chemotherapy is based on preclinical observations that PArP inhibitors preferentially kill neoplastic cells and induce complete or partial regression of a wide variety of human tumour xenografts in nude mice treated with platinum chemotherapy [60] [61] [62] . For example, ABT-888 (Abbott laboratories, Chicago, Illinois, USA), a potent inhibitor of PArP1 and PArP2, has been shown to potentiate the regression of established tumours induced by temozolomide, cisplatin, carboplatin or cyclophosphamide therapy in rodent orthotopic and xenograft models 63 . However, as stated above, the full function of PArP in DNA repair is not clear 57, 58 , and as a result the biological mechanisms of chemosensitization of cancer cells to platinum chemotherapy by PArP inhibition remain to be resolved. Interestingly, as a monotherapy in these preclinical models, ABT-888 exhibits no significant anticancer activity.
DNA demethylating agents such as 2′-deoxy-5-azacytidine (decitabine; MGI Pharma, Bloomington, Minnesota, USA) have been combined with cisplatin or carboplatin to reverse drug resistance caused by the silencing of mismatch repair genes by hypermethylation. The toxicity of agents such as cisplatin depends at least partly on functional mismatch repair (FIG. 1) . Preclinical data from xenograft models and translational studies from drug-resistant cells and tissues that are mismatch repair-deficient owing to MLH1 hypermethylation have demonstrated increased chemotherapeutic efficacy when a demethylating agent is combined with platinum chemotherapy 64, 65 . Decitabine is currently being tested in combination with carboplatin in a phase II clinical trial in patients with ovarian cancer (see Decitabine and Carboplatin in relapsed ovarian Cancer in Further information). It has been shown in preclinical models that the major cisplatin intra-strand crosslinks formed in DNA are recognized and repaired by the mammalian Ner pathway 66 . one biological predictor of clinical outcome for patients with completely resected non-small-cell lung cancer receiving adjuvant cisplatin-based chemotherapy is expression of the excision repair cross-complementation group 1 (erCC1) protein 67 . An immunohistochemical study of 761 operative specimens of non-small-cell lung cancer tissue taken before a proportion of the patients in the study received adjuvant chemotherapy showed that a significant benefit from cisplatin-based adjuvant chemotherapy was associated with the absence of erCC1 in 56% of the samples studied. The results suggested that patients with completely resected non-small-cell lung cancer and erCC1-negative tumours appeared to benefit from adjuvant cisplatin-based chemotherapy, whereas patients with erCC1-positive tumours did not. However, it should be noted that, among the patients who did not receive adjuvant chemotherapy, those with erCC1-positive tumours survived significantly longer than those with erCC1-negative tumours. It is therefore conceivable from the results of this study that erCC1 might not represent a biomarker specific to cisplatinbased chemotherapy, but it might represent a marker of prognosis and response to combination chemotherapy (not necessarily specific to cisplatin) in a poor-prognosis subset of patients, as has recently been demonstrated for p53 overexpression in a similar patient subgroup 68 . Although it has been suggested that erCC1 is a potential anticancer drug target, the protein has no known enzymatic activity, making the means of regulating its activity harder to decipher. Pharmacological modulation of erCC1 might therefore be less desirable than a greater understanding of the clinical relevance of protein-protein interactions within the Ner machinery or between erCC1 and other repair pathways, as potential targets for improving the efficacy of platinum chemotherapies. For example, UCN-01 (7-hydroxystaurosporine) is an anticancer agent that potentiates cisplatin and carboplatin toxicity (shown in preclinical models and a phase I clinical trial, respectively), which has been shown to interfere with the interaction of erCC1 and another component of the Ner pathway, xeroderma pigmentosum A (XPA), in vitro 69 .
Attenuators of checkpoint signalling. An alternative approach to modulating DNA repair activity and potentially improving the therapeutic index is to interfere with cell cycle checkpoint signalling. Xl844 (eXel-9844) is a small-molecule inhibitor of CHK1 and CHK2. This drug causes inhibition of cell-cycle arrest, progressive DNA damage, inhibition of DNA repair and, ultimately, tumour cell apoptosis in cancer cells grown in vitro 70 , although the outcome of inhibiting CHK1 and CHK2 in general can vary in a cell type-dependent manner. Although concerns have been raised about the potential toxicity to normal cells of an approach which inhibits both CHK1 and CHK2 kinases 71 , preclinical data have suggested that intermittent dosing with Xl844 in combination with the deoxycytidine analogue gemcitabine is well tolerated by female athymic nude mice used as a xenograft model 70 . Xl844 is currently being tested in a clinical trial (NCT00475917) in combination with gemcitabine, which normally causes cell-cycle arrest and apoptosis by its incorporation into DNA.
Two kinases from the phosphatidylinositol 3-kinase (PI3K)-related protein kinase (PIKKs) family, ATM and ATr, are central to cellular responses to DSBs. when activated, ATM and ATr phosphorylate a multitude of proteins, which initiate a cascade that induces cell-cycle arrest and facilitates DNA repair. An inhibitor of ATM kinase activity, KU55933 (AstraZeneca), is currently in preclinical development. The rationale behind the clinical use of ATM inhibitors depends on the premise that ATM inhibition should improve the therapeutic index by hypersensitizing tumour cells to agents that cause DSBs. Here again, the feasibility of inhibiting ATM kinase in patients will depend on the level of toxicity that such agents cause in normal tissues when they are used in combination with ionizing radiation or cytotoxic chemotherapy.
Radiosensitizers. DNA-dependent protein kinase (DNAPK, also known as PrKDC), a member of the PIKK family, is important for DSB repair by non-homologous end joining following ionizing radiation 72 . Cells defective in DNAPK are highly sensitive to ionizing radiation 73 indicating that inhibition of DNAPK might sensitize tumours to radiation treatment. wortmannin, a known inhibitor of PIKKs at low nanomolar concentrations, has antiproliferative effects and is a radiosensitizer in preclinical models 74 , but is unsuitable for clinical applications owing to its inherent toxicity and instability in cells 75 . other small molecules that reversibly inhibit DNAPK kinase activity at low micromolar concentrations have been synthesized. They are currently in transition from late preclinical development to early clinical trials. In particular, NU7441 (REF. 76 ) has been shown to sensitize cells to topoisomerase II poisons and can also function as a radiosensitizer in a manner consistent with DNAPK inhibition 77 .
DNA repair inhibitors as monotherapy
As discussed above, most of the current small-molecule inhibitors of DNA repair have so far been tested in early clinical trials as sensitizers of tumour cells to chemotherapy. However, DNA damage also occurs spontaneously in cells in the absence of treatments and DNA repair pathways are therefore essential for the survival of untreated cells. As several cancers are defective in DNA damage response and repair pathways (TABlE 2) , the concept of synthetic lethal interactions can be used to advocate the use of DNA repair inhibitors as monotherapies (FIG. 2) . DNA repair is an ideal target for inhibition in cancer cells as the inhibitors should be exclusively toxic to cancer cells and therefore be associated with minimal side effects for patients
.
Indeed, DNA repair inhibitors have been demonstrated to work as single agents in patients with DNA repair-defective tumours. The most notable example so far is the use of PArP inhibitors to treat patients with Synthetic lethalities observed in mammalian cells and the number of synthetic lethal interactions (SLIs) for their Saccharomyces cervisiae homologues are shown.
The genes showing SLIs with DNA repair genes can potentially be used as targets for novel drugs that then may selectively kill cancer cells in monotherapy.
A complete list of the SLIs in S. cervisiae can be found in Supplementary information S1 (table) . ATM, ataxia telangiectasia mutated; BER, base-excision repair; CHK, checkpoint kinase; ERCC, excision repair cross-complementation; FA, Fanconi anaemia-mediated repair; FANC, Fanconi anemia, complementation group; FEN1, flap structure-specific endonuclease 1; HR, homologous recombination; IR, infrared; MLH, mutL homologue; MMR, mismatch repair; MSH, mutS homologue; NER, nucleotide-excision repair; NHEJ, non-homologous end joining; PARP, poly(ADP-ribose) polymerase; RecQ, RecQ-mediated repair; SCE, sister chromatid exchange; UV, ultraviolet; XP, xeroderma pigmentosum. Nature Reviews | Cancer inherited breast and ovarian cancers that lack wild-type copies of the BRCA1 or BRCA2 genes 78, 79 . BRCA1-and BRCA2-mutated cells are defective in Hr repair 80, 81 and show extensive replication-associated lesions 82, 83 . These recombination-defective cells are 100-1,000-fold more sensitive to PArP inhibitors than are the heterozygote or the wild-type cell lines, indicating their potential to be exploited as specific treatments of BRCA1-or BRCA2-defective tumours 78, 79 . one explanation for this sensitivity is that PArP inhibitors induce single-strand breaks that can result in DSBs as a result of stalled replication forks. Such lesions would normally be repaired by Hr, but this is prohibited in BRCA1-or BRCA2-deficient cancer cells 79, [84] [85] [86] . PArP activity is also required for the actions of CHFr (checkpoint protein with forkhead-associated and ring finger domains) 58 and the reactivation of stalled replication forks 57 . These functions might also explain the hypersensitivity to PArP inhibitors of recombination-defective cells. Translation of these observations has led to phase II clinical trials of monotherapy using the PArP inhibitor AZD2281 (AstraZeneca) currently recruiting patients with breast and ovarian cancer who harbour mutations in BRCA1 or BRCA2 genes. A separate phase II trial with the PArP1 inhibitor AG014699 (Pfizer GrD) is due to open to recruitment of known carriers of BRCA1 or BRCA2 mutations with locally advanced or metastatic cancers of the breast or ovaries. It should be noted however that not all patients with mutations in BRCA1 or BRCA2 respond to PArP inhibitors as a monotherapy. The reasons for this are currently under investigation. Cells that are defective in recombination-related proteins other than BrCA1 or BrCA2, such as rAD51, rAD54, XrCC2, XrCC3, DSS1 (also known as SHFM1), replication protein A1 (rPA1), ATM, ATr, CHK1, CHK2, NBS1 (also known as NBN) and components of the Fanconi anaemia repair pathway, also show increased sensitivity to PArP inhibition 79, 87, 88 . This suggests that PArP inhibitors might also be suitable in treating several types of tumours with defects in Hr.
Another synthetic lethal interaction has recently been discovered between the Fanconi anaemia repair pathway and ATM. Two pancreatic tumour lines defective in the Fanconi anaemia pathway were more sensitive to the ATM inhibitor KU-55933 than isogenic control cells 89 . This finding provides a rationale for studying ATM inhibitors in the treatment of Fanconi anaemia repair-defective pancreatic cancer.
Finding new synthetic lethal DNA repair-based partnerships. As mutations in checkpoint and DNA repair pathways are associated with cancer (TABlE 2) , it should be straightforward to exploit DNA repair inhibitors for the treatment of tumours carrying specific defects in DNA repair or damage signalling (FIG. 2) . Genomewide screens in model organisms, such as the budding yeast Saccharomyces cerevisiae, have helped to identify protein interaction networks, which serve to elucidate protein functions within highly complex cellular processes. Such knowledge can prove extremely useful in identifying suitable targets for monotherapy, but perhaps more significantly those that could be used in combination therapies. we have compiled a list of reported mutations in DNA damage response genes found in human tumours and homologous synthetic lethal interactions that have been demonstrated in . Here, we use synthetic lethal interactions in Saccharomyces cerevisiae to illustrate a hypothetical scenario. a | We start with an Mre11 mutation that is found in mismatch repair-defective tumours 108 . b | The yeast mre11 is synthetic lethal with topoisomerase III (Top� �) 109 . If the synthetic lethal interaction is conserved from yeast to man, inhibitors of Top3 would, in theory, kill Mre11-mutated tumour cells. Top�-mutated yeast cells are viable, albeit with genetic instability 110 , and thus Top3 inhibitors may specifically kill Mre11-mutated cancer cells while being tolerated in normal cells. c | Replication repair networks are complex and an additional mutation might override synthetic lethal interactions. In yeast, an additional mutation in sgs1, upstream of the hypothetically targeted TOP� pathway, reverses the synthetic lethal phenotype 109 . Thus, in this scenario, an additional tumour mutation in the human homologue of SGS1, BLM, might result in resistance to Top3 inhibitors. d | sae2 is in turn synthetic lethal with sgs1 in yeast 111 . If this synthetic lethal interaction is conserved, the human SAE2 homologue CtIP (also known as retinoblastoma binding protein 8 (RBBP8)) might, in theory, then be targeted as a second-line therapy in Top3 inhibitor-resistant tumours that gained resistance owing to a BLM mutation. In summary, understanding of DNA repair networks is important to identify pathways to target and to circumvent resistance mechanisms. 
S. cerevisiae (Supplementary information S1 (table)
). This information could be used to identify proteins encoded by the human homologues of genes showing synthetic lethal interactions that may represent good targets for specific treatment of cancers carrying mutations in DNA repair genes. Unfortunately, the poorly defined biochemical properties of these proteins are still a significant barrier to the exploitation of these proteins as potential targets for drug intervention in the immediate future.
A further limitation to exploiting these pathways is the lack of reliable biomarkers to aid the selection of patients that might respond to such treatments. This is particularly important as cancers in patients that have no DNA repair defect will not respond. The most reliable biomarkers will probably be those that identify loss of specific post-translational modifications present in the DNA damage response and repair pathways, or those that indicate increased activity of the targeted pathway.
Future directions
Current chemotherapy regimens demonstrate that production of excessive replication lesions is a successful means of killing cancer cells. It has been observed that tumour cells themselves exhibit a high level of endogenous replication lesions that result in genetic instability 32, 33, 90 . In theory, DNA repair inhibitors could be used to impair the repair of replication lesions that are present in tumour cells and convert them into fatal replication lesions that specifically kill cancer cells. For example, there is evidence that the increased expression or activity of oncogenes can induce replication stress 32, 33, 91, 92 . In such tumours it might be possible to use DNA repair inhibitors to make existing cancer-specific replication lesions more toxic, resulting in fatal replication lesions selectively killing oncogeneexpressing cancer cells 32, 33, 
More advanced cancers are exposed to another source of replication stress owing to the tumour microenvironment. Tumours are often hypoxic, which has been shown to disrupt DNA synthesis 98 . These conditions cause replication lesions that activate the ATM-and ATr-mediated checkpoint response [99] [100] [101] . Furthermore, DNA repair is downregulated in hypoxic cells 102 , which cumulatively contributes to the genetic instability observed in these cells 103, 104 . In hypoxic cancer cells, therefore, inhibitors of the checkpoint response could prove to be more efficient than inhibitors of DNA repair 105 .
Conclusions
The potential of inhibitors of DNA repair in the future of cancer therapy is starting to become apparent. Although selective inhibition of DNA repair pathways can be used to enhance current chemotherapy, the most attractive use of DNA repair inhibitors might be in using cancer defects for selective cell killing. DNA Box 2 | Advantages and limitations using DNA repair inhibitors as single agents in treatment of cancers
• DNA repair inhibitors can exploit tumour-specific defects in checkpoint signalling and DNA repair to convert endogenous DNA lesions into fatal replication lesions that selectively kill tumour cells.
• A general problem for novel cancer therapies is that they are not sufficiently efficient at killing cancer cells to replace current cytotoxic therapies. As a result, some enzyme inhibitors (that do not target DNA repair) have failed in late clinical trial development owing to a general lack of anti-tumour efficacy. Inhibition of DNA repair amplifies toxic replication-associated DNA lesions that directly result in cell death. DNA repair inhibitors might therefore be highly efficient at killing tumours.
• Cross-talk between DNA repair pathways in normal cells minimizes side effects from the inhibition of a single DNA repair pathway.
• Tumour inactivation of DNA damage signalling and DNA repair are often relatively early events during carcinogenesis, suggesting that non-toxic DNA repair inhibitors may be considered in the treatment of patients with pre-malignant or early neoplastic lesions, such as those arising in patients with inherited mutations in BRCA1 or BRCA2 genes, or intestinal lesions in patients with defects in MLH1 and MSH2 genes or their methylation status.
• Cross-talk between DNA repair pathways, such as the cross-talk between homologous recombination and nonhomologous end joining in the repair of DNA double-strand breaks or the cross-talk between base-excision repair, alkyltransferases and DNA dioxygenases in the repair of alkylation damage, is likely to result in acquisition of resistance mechanisms in tumours, which is a limitation for killing more advanced tumours.
Box 3 | Targetting oncogene-induced replication stress
The transformation of normal cells to a cancerous state is often initiated by the activation of oncogenes, which provide excessive growth signals 106 . It was recently shown that such oncogene activation can induce replication-associated DNA lesions 32, 33, 91, 92 , including increased replication origin firing, re-replication and impaired fork progression 32, 107 . These replication-associated lesions trigger a cell-cycle checkpoint response that stops the proliferation of pre-cancerous cells early during neoplastic transformation 32, 33, [91] [92] [93] . This involves checkpoint proteins, such as p53 and CHK2, that can induce apoptosis or senescence 94, 95 , Genes encoding proteins in the checkpoint pathways are often mutated during cancer development 96 , allowing cells to evade checkpoints and continue to proliferate. Taken together, these observations suggest that a key feature of cancer cells that overexpress oncogenes might be higher levels of endogenous replicationassociated lesions than those present in normal cells. This in turn would contribute to genetic instability 97 that would assist the tumour to induce the genetic changes required for continuing transformation to malignant phenotypes 90 . More importantly, the replication lesions caused by oncogene activation have been found to resemble those produced by anticancer treatments 32 , and, like the latter, these lesions would require repair for the cancer cells to survive. We therefore propose that future DNA repair inhibitors should be used to make existing cancer-specific replication lesions more toxic, resulting in fatal replication lesions selectively killing oncogeneexpressing cancer cells. The nature of the replication lesions that are produced following chemotherapy or oncogene-induced stress are poorly understood. Although several replication repair pathways have been identified, we currently have little information regarding their complex interplay. Indeed, more intense basic research is required in this area to identify novel anticancer targets.
repair inhibitors that exploit tumour mutations in DNA repair pathways to convert spontaneous DNA lesions into fatal replication lesions might represent the most direct means of finding selective treatments for certain cancers. This type of therapy is highly advantageous when compared with current chemotherapy as it is likely to produce minimal side effects while resulting in highly toxic lesions that should actively trigger cell death in cancer cells. A potential limitation of this approach is that it is likely to be confined to DNA repair-defective tumours and that resistance mechanisms might develop.
A more challenging treatment strategy is the inhibition of the repair of tumour-specific replication lesions and conversion of these into fatal lesions. replication stress appears to be present in a majority of tumours during at least one stage of carcinogenesis. Thus, the conversion of replication stress into fatal replication lesions could potentially be used to target a wide range of tumours. As we are still unaware of the exact nature of the replication lesions that are induced by many traditional chemotherapies, there is still considerable work to be done in characterizing tumourspecific lesions to target cancers. Basic research into understanding the nature of toxic replication lesions, as well as obtaining a more complete picture of all DNA repair pathways and their interplay, is crucial for the future of DNA repair inhibitors as single agents in cancer therapy.
In summary, cancer cells are potentially exposed to unusually high levels of replication stress and endogenous DNA damage during cancer development. A future challenge will be to identify and characterize forms of replication lesions occurring during carcinogenesis and neoplastic progression that may be exploited for selective therapy.
